The stock of Amylyx Pharmaceuticals Inc (AMLX) has seen a 4.95% increase in the past week, with a 28.82% gain in the past month, and a 96.71% flourish in the past quarter. The volatility ratio for the week is 6.57%, and the volatility levels for the past 30 days are at 7.49% for AMLX. The simple moving average for the past 20 days is 15.48% for AMLX’s stock, with a 51.94% simple moving average for the past 200 days.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
AMLX has 36-month beta value of -0.48. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AMLX is 65.31M, and currently, short sellers hold a 6.19% ratio of that float. The average trading volume of AMLX on July 03, 2025 was 1.24M shares.
AMLX) stock’s latest price update
The stock price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) has jumped by 2.50% compared to previous close of $6.41. Despite this, the company has seen a gain of 4.95% in its stock price over the last five trading days. fool.com reported 2025-06-27 that Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with Guggenheim repeating the rating for AMLX by listing it as a “Buy.” The predicted price for AMLX in the upcoming period, according to Guggenheim is $17 based on the research report published on June 24, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $12. The rating they have provided for AMLX stocks is “Buy” according to the report published on June 17th, 2025.
AMLX Trading at 24.78% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from FRATES JAMES M, who sale 10,896 shares at the price of $3.47 back on Mar 31 ’25. After this action, FRATES JAMES M now owns 290,988 shares of Amylyx Pharmaceuticals Inc, valued at $37,806 using the latest closing price.
Bedrosian Camille L, the Chief Medical Officer of Amylyx Pharmaceuticals Inc, sale 12,425 shares at $3.47 during a trade that took place back on Mar 31 ’25, which means that Bedrosian Camille L is holding 194,375 shares at $43,082 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- 163.17 for the present operating margin
- 7.76 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at 172.06. The total capital return value is set at -1.03. Equity return is now at value -83.24, with -68.70 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -149.77.
Currently, EBITDA for the company is -301.23 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -414.52. The receivables turnover for the company is -4.24for trailing twelve months and the total asset turnover is -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.05.
Conclusion
To put it simply, Amylyx Pharmaceuticals Inc (AMLX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
